These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12670654)

  • 1. Design and synthesis of broad-based mono- and bi- cyclic inhibitors of FIV and HIV proteases.
    Mak CC; Brik A; Lerner DL; Elder JH; Morris GM; Olson AJ; Wong CH
    Bioorg Med Chem; 2003 May; 11(9):2025-40. PubMed ID: 12670654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3' residue.
    Mak CC; Le VD; Lin YC; Elder JH; Wong CH
    Bioorg Med Chem Lett; 2001 Jan; 11(2):219-22. PubMed ID: 11206463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.
    Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH
    Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.
    Le VD; Mak CC; Lin YC; Elder JH; Wong CH
    Bioorg Med Chem; 2001 May; 9(5):1185-95. PubMed ID: 11377177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease.
    Li M; Morris GM; Lee T; Laco GS; Wong CH; Olson AJ; Elder JH; Wlodawer A; Gustchina A
    Proteins; 2000 Jan; 38(1):29-40. PubMed ID: 10651036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
    Lin YC; Brik A; de Parseval A; Tam K; Torbett BE; Wong CH; Elder JH
    J Virol; 2006 Aug; 80(16):7832-43. PubMed ID: 16873240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease.
    Lin YC; Beck Z; Lee T; Le VD; Morris GM; Olson AJ; Wong CH; Elder JH
    J Virol; 2000 May; 74(10):4710-20. PubMed ID: 10775609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
    Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
    J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.
    Beck ZQ; Lin YC; Elder JH
    J Virol; 2001 Oct; 75(19):9458-69. PubMed ID: 11533208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.
    Heaslet H; Lin YC; Tam K; Torbett BE; Elder JH; Stout CD
    Retrovirology; 2007 Jan; 4():1. PubMed ID: 17212810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of pseudopeptide inhibitors of HIV-1 aspartic protease: analysis and tuning of the subsite specificity.
    Tossi A; Antcheva N; Romeo D; Miertus S
    Pept Res; 1995; 8(6):328-34. PubMed ID: 8838416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.
    Lin YC; Torbett BE; Elder JH
    J Virol; 2010 Jul; 84(13):6799-809. PubMed ID: 20410281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.
    Dunn BM; Pennington MW; Frase DC; Nash K
    Biopolymers; 1999; 51(1):69-77. PubMed ID: 10380354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency comparison of peptidomimetic inhibitors against HIV-1 and HIV-2 proteinases: design of equipotent lead compounds.
    Weber J; Majer P; Litera J; Urban J; Soucek M; Vondrásek J; Konvalinka J; Novek P; Sedlácek J; Strop P; Kräusslich HG; Pichová I
    Arch Biochem Biophys; 1997 May; 341(1):62-9. PubMed ID: 9143353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV.
    Kervinen J; Lubkowski J; Zdanov A; Bhatt D; Dunn BM; Hui KY; Powell DJ; Kay J; Wlodawer A; Gustchina A
    Protein Sci; 1998 Nov; 7(11):2314-23. PubMed ID: 9827997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
    Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
    Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors.
    Calugi C; Guarna A; Trabocchi A
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):936-43. PubMed ID: 22803674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays.
    Dreyer GB; Lambert DM; Meek TD; Carr TJ; Tomaszek TA; Fernandez AV; Bartus H; Cacciavillani E; Hassell AM; Minnich M
    Biochemistry; 1992 Jul; 31(29):6646-59. PubMed ID: 1637805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide inhibitors of HIV-1 and HIV-2 proteases: a comparative study.
    Pichová I; Weber J; Litera J; Konvalinka J; Vondrásek J; Soucek M; Strop P; Majer P; Heuser AM; Kraeusslich HG
    Leukemia; 1997 Apr; 11 Suppl 3():120-2. PubMed ID: 9209317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
    Ekegren JK; Unge T; Safa MZ; Wallberg H; Samuelsson B; Hallberg A
    J Med Chem; 2005 Dec; 48(25):8098-102. PubMed ID: 16335934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.